Abstract
Virtually all patients with a newly discovered pleural effusion should undergo thoracentesis to aid in diagnosis and management. Pleural fluid (PF) samples should be collected into heparinized tubes to prevent clot formation. The routine PF evaluation usually includes cell count and differential, protein, lactate dehydrogenase, glucose, adenosine deaminase, cytology and, if infection is a concern, pH as well as bacterial and mycobacterial cultures. Distinguishing transudates from exudates through Lights criteria is a pragmatic first step. If the effusion is an exudate, various PF tests have proven diagnostic utility: adenosine deaminase levels > 40 U/L usually indicate tuberculosis in lymphocytic-predominant PFs or empyema in neutrophilic-predominant PFs; pH < 7.2 and glucose < 60 mg/dL allow the clinician to identify complicated parapneumonic effusions and guides their initial management; and conventional cytology may demonstrate malignant cells in 60% of the patients with malignant effusions. A number of optional PF tests may complement the diagnostic approach to an undiagnosed pleural effusion. For example, natriuretic peptide assays significantly improve the accuracy of the diagnosis of cardiac pleural effusions; PF mesothelin levels greater than 20 nM are highly suggestive of mesothelioma; and new molecular techniques have improved the identification of the causative organisms in pleural infections.
Keywords: Pleural effusion, exudates, pleural infection, malignant pleural disease
Current Respiratory Medicine Reviews
Title: Pleural Fluid Analysis for Evaluating Pleural Effusions
Volume: 4 Issue: 3
Author(s): Jose M. Porcel and Richard W. Light
Affiliation:
Keywords: Pleural effusion, exudates, pleural infection, malignant pleural disease
Abstract: Virtually all patients with a newly discovered pleural effusion should undergo thoracentesis to aid in diagnosis and management. Pleural fluid (PF) samples should be collected into heparinized tubes to prevent clot formation. The routine PF evaluation usually includes cell count and differential, protein, lactate dehydrogenase, glucose, adenosine deaminase, cytology and, if infection is a concern, pH as well as bacterial and mycobacterial cultures. Distinguishing transudates from exudates through Lights criteria is a pragmatic first step. If the effusion is an exudate, various PF tests have proven diagnostic utility: adenosine deaminase levels > 40 U/L usually indicate tuberculosis in lymphocytic-predominant PFs or empyema in neutrophilic-predominant PFs; pH < 7.2 and glucose < 60 mg/dL allow the clinician to identify complicated parapneumonic effusions and guides their initial management; and conventional cytology may demonstrate malignant cells in 60% of the patients with malignant effusions. A number of optional PF tests may complement the diagnostic approach to an undiagnosed pleural effusion. For example, natriuretic peptide assays significantly improve the accuracy of the diagnosis of cardiac pleural effusions; PF mesothelin levels greater than 20 nM are highly suggestive of mesothelioma; and new molecular techniques have improved the identification of the causative organisms in pleural infections.
Export Options
About this article
Cite this article as:
Porcel M. Jose and Light W. Richard, Pleural Fluid Analysis for Evaluating Pleural Effusions, Current Respiratory Medicine Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339808785161369
DOI https://dx.doi.org/10.2174/157339808785161369 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Current Pharmaceutical Design Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering